Get started
Author

RA Beckman

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
2002 · M Gore, A Oza, et al. · European Journal of Cancer · 107
Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker
2016 · RA Beckman, Z Antonijevic, et al. · Clinical Pharmacology & Therapeutics · 67
Oral Topotecan as Single-Agent Second-Line Chemotherapy in Patients With Advanced Ovarian Cancer
2001 · D. L. Clarke-Pearson, L. Van Le, et al. · Journal of Clinical Oncology · 55
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
2016 · MR Trusheim, AA Shrier, et al. · Clinical Pharmacology & Therapeutics · 44
PDF
Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors
2005 · G. C. Jayson, S. Mullamitha, et al. · Journal of Clinical Oncology · 18
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
2001 · M Gore, G Rustin, et al. · British Journal of Cancer · 15
PDF
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)
2015 · J von Pawel, J Tseng, et al. · Pneumologie · 4
Topotecan: tolerability, response rate and survival associated with extended therapy in relapsed ovarian cancer — Results of a pooled analysis of 523 patients
1999 · V. Mobus, S. Lane, et al. · European Journal of Cancer · 3
Utilizing Real-World Data to Inform a Confirmatory Basket Trial Design: Studying Use of Rituximab in Autoimmune Diseases
2018 · D Guinn, Y Ren, et al. · Value in Health · 2
Abstract P4-16-09: Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+ metastatic breast cancer (MBC)
2013 · S Carraro, D Campos, et al. · Cancer Research · 2
A phase I/II study using oral topotecan (OT) with intravenous paclitaxel (P) as first-line therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC)
2000 · J.R Eckardt, M.P Fanucchi, et al. · Lung Cancer · 2
Integrating predictive biomarkers and classifiers into oncology clinical development programs
2014 · R. A. Beckman · AACR Education book · 1
Phase I study of CNTO 95, a fully human monoclonal antibody to αv integrins, docetaxel, and prednisone in hormone refractory prostate cancer patients (HRPCP)
2007 · F. M. Chu, J. Picus, et al. · Journal of Clinical Oncology · 1
CNTO 95, a fully human monoclonal antibody to alpha-v integrins: results of a phase I/II study in patients with metastatic melanoma
2006 · S. O??Day, J. Richards, et al. · Melanoma Research · 1
Towards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure
2026 · Robert A Beckman, Pamela S Becker, et al. · Stem Cells Translational Medicine
Additional file 1: of Long range personalized cancer treatment strategies incorporating evolutionary dynamics
2016 · Yeang, Chen-Hsiang, Beckman, Robert · Figshare
240 Molecular imaging of Death Receptor 5 (DR5) occupancy in-vivo by humanized monoclonal antibody CS-1008
2010 · A.M. Scott, F.T. Lee, et al. · European Journal of Cancer Supplements
218 POSTER Phase I/II study of CNTO 95, a fully human monoclonal antibody (mAb) to alpha-v integrins, in patients with metastatic melanoma
2006 · S. O' Day, J. Richards, et al. · European Journal of Cancer Supplements
Works count: 18
Citation count: 322
H-index: 6
I10-index: 6
Year
Topic
Type